COMMUNIQUÉS West-GlobeNewswire

MDxHealth_FY_Results FR

22/02/2018 - 07:01

COMMUNIQUÉ DE PRESSE INFORMATION REGLEMENTÉE RAPPORT FINANCIER ANNUEL MDxHealth communique ses résultats financiers pour l'exercice 2017 Le chiffre d'affaires total est en hausse de 35 % et les revenus liés aux produits [...]

Biocartis Group NV: Biocartis to host webcast for announcement 2017 financial results on 1 March 2018

22/02/2018 - 07:01

PRESS RELEASE: REGULATED INFORMATION 22 February 2018, 07:00 CET BioCARTIS to Host Webcast FOR ANNOUNCEMENT 2017 FINANCIAL Results on 1 March 2018 Mechelen, Belgium, 22 February 2018 - Biocartis Group NV (the 'Company' [...]

argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018

22/02/2018 - 07:01

February 22, 2018 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

22/02/2018 - 05:45

COPENHAGEN, Denmark, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,947,368 [...]

Primary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease

22/02/2018 - 00:00

NEW YORK and MELBOURNE, Australia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) today announced that the Phase 3 trial of its allogeneic mesenchymal stem cell product candidate MSC-100- [...]

Genesis Announces New Financing Commitments and Provides Updates to Previously Announced Restructuring Plans

21/02/2018 - 23:43

$70 Million of Additional Liquidity from New and Expanded Loan Commitments $54 Million of Annual Lease Reductions Effective January 1, 2018 KENNETT SQUARE, Pa., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare (NYSE [...]

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

21/02/2018 - 23:26

BRIDGEWATER, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of [...]

Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine

21/02/2018 - 23:00

– Marked and Durable Responses Across TRK Fusion Cancers – – 75 Percent Overall Response Rate by Central Assessment; 80 Percent Overall Response Rate by Investigator Assessment – – 86 Percent of Responding Patients [...]

Integra LifeSciences to Present at Healthcare Conferences in March 2018

21/02/2018 - 22:30

PLAINSBORO, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART ), a leading global medical technology company, will present at the following healthcare conferences in March: [...]

SeaSpine to Report Fourth Quarter and Full Year 2017 Financial Results on February 28, 2018

21/02/2018 - 22:30

CARLSBAD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE ), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]

Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock

21/02/2018 - 22:30

CRANBURY, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) today announced the closing of its previously announced offering of common stock. The Company issued a total of 19,354,839 shares in [...]

ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until March 9, 2018

21/02/2018 - 22:30

3 of 4 Proposals pass with stockholder approval Annual Meeting adjourned solely with respect to Proposal 4 - Approval of Reverse Stock Split EDISON, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc [...]

Globus Medical Reports Full Year and Fourth Quarter 2017 Results

21/02/2018 - 22:15

AUDUBON, Pa., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED ), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, [...]

LeMaitre Q4 2017 Record Sales $26.2mm (+12%), Record Op. Income $6.3mm (+62%)

21/02/2018 - 22:06

BURLINGTON, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT ), a provider of vascular devices, implants and services, today reported Q4 2017 results, provided guidance, and announced a 27 [...]

Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018

21/02/2018 - 22:06

Launches Search for Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing [...]

TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018

21/02/2018 - 22:05

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON ), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer [...]

GenMark Diagnostics to Present at Upcoming Investor Conferences

21/02/2018 - 22:03

CARLSBAD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK ) today announced that the Company plans to participate in two upcoming investor conferences. March 1, 2018, GenMark’s [...]

G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights

21/02/2018 - 22:01

Topline data expected in March 2018 from first of three ongoing Phase 2 trials evaluating the myelopreservation benefits of trilaciclib Management to host webcast and conference call today at 4:30 p.m. EST RESEARCH [...]

GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006

21/02/2018 - 22:01

-Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’s potential within the field of epilepsy- [...]